Patents Assigned to BIOATLA, Inc.
-
Publication number: 20240117067Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.Type: ApplicationFiled: November 14, 2023Publication date: April 11, 2024Applicant: BioAtla, Inc.Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20240092901Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Ror2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.Type: ApplicationFiled: August 29, 2023Publication date: March 21, 2024Applicant: BioAtla, Inc.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11897959Abstract: An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.Type: GrantFiled: September 3, 2021Date of Patent: February 13, 2024Assignee: BIOATLA, INC.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20240044046Abstract: Methods of generating conditionally active proteins that target senescent cells and which are conditionally active in an extracellular environment of a senescent cell. The methods include methods using libraries of evolved proteins and assays employing physiological concentrations of components of bodily fluids. Also disclosed are conditionally active proteins for killing or removing senescent cells, antibodies and antibody fragments, conjugates and pharmaceutical compositions employing these conditionally active proteins and methods for treatment of age-related diseases, conditions or disorders using same. The conditionally active proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety.Type: ApplicationFiled: May 7, 2023Publication date: February 8, 2024Applicant: BioAtla, Inc.Inventor: Jay Short
-
Patent number: 11879011Abstract: A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.Type: GrantFiled: November 23, 2021Date of Patent: January 23, 2024Assignee: BIOATLA, INC.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11859007Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.Type: GrantFiled: September 24, 2020Date of Patent: January 2, 2024Assignees: CORVUS PHARMACEUTICALS, INC., BIOATLA, INC.Inventors: Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
-
Patent number: 11851499Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.Type: GrantFiled: June 10, 2020Date of Patent: December 26, 2023Assignee: BioAtla, Inc.Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Patent number: 11834472Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.Type: GrantFiled: June 4, 2019Date of Patent: December 5, 2023Assignee: BIOATLA, INC.Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
-
Publication number: 20230374702Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.Type: ApplicationFiled: June 27, 2023Publication date: November 23, 2023Applicant: BioAtla, Inc.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20230332135Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: June 14, 2023Publication date: October 19, 2023Applicant: BIOATLA, INC.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11773509Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.Type: GrantFiled: August 13, 2021Date of Patent: October 3, 2023Assignee: BioAtla, Inc.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11718844Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: September 8, 2017Date of Patent: August 8, 2023Assignee: BIOATLA, INC.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20230242662Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to CD46 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CD46 protein. Immunoconjugages, pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.Type: ApplicationFiled: June 15, 2021Publication date: August 3, 2023Applicant: BIOATLA, INC.Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING
-
Publication number: 20230235054Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to Nectin-4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Nectin-4 protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.Type: ApplicationFiled: June 15, 2021Publication date: July 27, 2023Applicant: BIOATLA, INC.Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING, Haizhen LIU, Ana Paula CUGNETTI
-
Publication number: 20230192858Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.Type: ApplicationFiled: November 17, 2022Publication date: June 22, 2023Applicant: BioAtla, Inc.Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20230183679Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.Type: ApplicationFiled: December 2, 2022Publication date: June 15, 2023Applicant: BioAtla, IncInventor: Jay M. Short
-
Patent number: 11639365Abstract: The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.Type: GrantFiled: September 30, 2020Date of Patent: May 2, 2023Assignee: BioAtla, Inc.Inventor: Jay M. Short
-
Publication number: 20230109218Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to HER2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to HER2 protein and multi-specific antibodies that bind to HER2 protein and CD3.Type: ApplicationFiled: January 22, 2021Publication date: April 6, 2023Applicant: BioAtla, Inc.Inventors: Jay M. SHORT, Gerhard FREY, Hwai Wen Chang
-
Publication number: 20230072955Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.Type: ApplicationFiled: January 23, 2021Publication date: March 9, 2023Applicants: Exuma Biotech Corp, BioAtla, Inc.Inventors: Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Patent number: 11584927Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.Type: GrantFiled: August 2, 2018Date of Patent: February 21, 2023Assignee: BioAtla, Inc.Inventor: Jay M. Short